科研之友
微信
新浪微博
Facebook
分享链接
摘要
Epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are with clinical benefits. Nevertheless, eventual resistance to EGFR-TKI is almost inevitable. In about 50% patients, EGFR-TKI develops a secondary mutation, which is often the T790M mutation. We aimed to investigate the relationship between EGFR gene status in the peripheral blood and prognosis (progression-free survival [PFS] and overall survival [OS]) in advanced lung adenocarcinoma patients and the 20 exon 790 site mutation (T790M) and acquired resistance to EGFR-TKI. A total of 49 patients with EGFR-TKI resistance and advanced lung cancer who visited the Shihezi University School of Medicine between 12/2013 and 12/2014 were enrolled in this study. Peripheral blood plasma DNA was isolated after EGFR-TKI resistance and the EGFR exon 20 T790M mutation was detected using the probe amplification refractory mutation system method. The T790M mutation rate was 30.6% (15/49). There was no association between T790M mutation and age, gender, smoking, clinical stage, Eastern Cooperative Oncology Group rating, initial EGFR mutation, and EGFR-TKI drugs, but EGFR-TKI resistance was associated with progression (P=.009). Median progression-free survival (PFS) of patients with T790Mmutation was 9.6 months and median overall survival (OS) was 17.6 months, compared to 6.8 and 12.7 months in controls (P=. 018 and P=. 027). Multivariate analysis showed that T790M mutations independently affected the PFS (risk ratio, RR=0.653, 95% confidence interval, CI: 0.0690.886, P=.032) and OS (RR=0.847, 95% CI: 0.208-2.696, P=.008). T790M mutation and EGFR-TKI resistance are independent factors to affect PFS and OS of non-small cell lung cancer patients.
